D-0387-2025 Class II Ongoing
FDA drug recall D-0387-2025 was initiated by Breckenridge Pharmaceutical, Inc on Apr 14, 2025 and is designated Class II. Reason for recall: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit. The recall status is ongoing. Affected quantity: 16,473 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 30, 2025
- Initiation Date
- Apr 14, 2025
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 16,473 bottles
Product description
Duloxetine Delayed-Release Capsules USP, 60 mg, 1000-count bottles, Rx Only, Manufactured by Towa Pharmaceutical Europe, S.L., Distributed by Breckenridge Pharmaceutical, Inc. Berkeley Heights, NJ 07922, NDC# 51991-748-10
Reason for recall
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Distribution pattern
US Nationwide.
Code information
Lot # 240987C, exp. date 04/2027 241014C, exp. date 04/2027
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0387-2025
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026